CRISPR Therapeutics reports 65% ANGPTL3 and 63% triglyceride reductions with CTX310 in Phase 1b trial

CRISPR Therapeutics reports CTX310 achieved 65% ANGPTL3 and 63% triglyceride reductions in a Phase 1b trial for severe hypertriglyceridemia, and was well tolerated with no treatment-related serious adverse events and no clinically relevant elevations in liver transaminases.

Detected & updated continuously · Source: Nebula